Statins reduce respiratory complications of COPD.

Am J Med

Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Published: January 2014

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2013.07.041DOI Listing

Publication Analysis

Top Keywords

statins reduce
4
reduce respiratory
4
respiratory complications
4
complications copd
4
statins
1
respiratory
1
complications
1
copd
1

Similar Publications

Statement Of Problem: Denture stomatitis (DS) is a common oral disorder in patients with complete maxillary dentures. Typical treatments such as nystatin or azoles lead to drug resistance after a long period. Several studies have shown the antifungal activity of statins against Candida albicans; however, studies on the antifungal effect of atorvastatin against DS are lacking.

View Article and Find Full Text PDF

Statin use after cancer diagnosis and survival among patients with cancer.

Cancer Causes Control

December 2024

Division of Public Health Sciences, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, M4-C308, Seattle, WA, 98019, USA.

Purpose: The association between statin use and cancer survival has been investigated in previous studies with conflicting findings. This study aimed to assess the association between statin use following cancer diagnosis and survival in six common cancers using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database.

Methods: Individuals aged ≥ 66 years diagnosed with prostate cancer, colorectal cancer, lung cancer, bladder cancer, pancreatic cancer, or non-Hodgkin lymphoma (NHL) from 2008 through 2017 were identified.

View Article and Find Full Text PDF

Objectives: This review aims to examine the evidence on the benefits and risks of lipid lowering drugs in patients with liver disease. Elevated liver enzyme levels often lead to cautious discontinuation of these drugs, potentially withholding from patients their benefit in reducing cardiovascular disease morbidity and mortality.

Methods And Results: Using a literature search of PubMed, we examine the efficacy and safety profiles of various lipid lowering agents, including statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, and icosapent ethyl, focusing particularly on their potential side effects related to liver health.

View Article and Find Full Text PDF

Metabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians.

J Prim Care Community Health

December 2024

Lehigh Valley Health Network Family Medicine Residency, Allentown, PA, USA.

Objective: Metabolic syndrome is a cluster of cardiovascular risk factors (central obesity, hypertension, dyslipidemia, and insulin resistance) that affects between 12.5% and 31.4% of adults worldwide.

View Article and Find Full Text PDF

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease with a significant risk of developing hepatocellular carcinoma (HCC). Recent clinical evidence indicates the potential benefits of statins in cancer chemoprevention and therapeutics. However, it is still unclear if these drugs can lower the specific risk of HCC among patients with MASLD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!